HUP0301887A2 - Több részecskébżl álló gyógyszerforma, amely legalább két különbözżen bevont pelletformát tartalmaz - Google Patents

Több részecskébżl álló gyógyszerforma, amely legalább két különbözżen bevont pelletformát tartalmaz

Info

Publication number
HUP0301887A2
HUP0301887A2 HU0301887A HUP0301887A HUP0301887A2 HU P0301887 A2 HUP0301887 A2 HU P0301887A2 HU 0301887 A HU0301887 A HU 0301887A HU P0301887 A HUP0301887 A HU P0301887A HU P0301887 A2 HUP0301887 A2 HU P0301887A2
Authority
HU
Hungary
Prior art keywords
pellet
active ingredient
medicament
polymer
hours
Prior art date
Application number
HU0301887A
Other languages
English (en)
Inventor
Thomas Beckert
Jennifer Dressman
Hans-Ulrich Petereit
Markus Rudolph
Original Assignee
Röhm GmbH & Co. KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10104880A external-priority patent/DE10104880A1/de
Application filed by Röhm GmbH & Co. KG filed Critical Röhm GmbH & Co. KG
Publication of HUP0301887A2 publication Critical patent/HUP0301887A2/hu
Publication of HUP0301887A3 publication Critical patent/HUP0301887A3/hu
Publication of HU229291B1 publication Critical patent/HU229291B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány több részecskéből álló gyógyszerformára vonatkozik, amelyegy hatóanyagnak a vékonybélben és a vastagbélben való egyenletesleadására alkalmas, és amely legalább két, A és B pelletformát foglalmagában, amelyek a magban gyógyhatású komponenst tartalmaznak éseltérő polimer bevonattal vannak ellátva, amely bevonatok ahatóanyagnak különböző pH-értékeknél való leadását határozzák meg, agyógyszerformára jellemző, hogy az A pelletforma egy belső polimerbevonattal, amely lehetővé teszi a hatóanyag folyamatos leadását, ésegy külső, enterális bevonattal van ellátva, amely kb. 5,5 feletti pH-n gyorsan feloldódik, és a B pelletforma egy olyan polimer bevonattalvan ellátva, amely a USP hatóanyag-felszabadulási tesztben a hatóanyagkevesebb, mint 20%-át adja le 6,8-es pH-n 6 óra alatt, és a hatóanyagtöbb, mint 50%-át adja le 7,2-es pH-n 6 óra alatt. A találmány tárgyátképezi a több részecskéből álló gyógyszerforma előállítására alkalmaseljárás és az A és B pelletforma gyógyszerforma előállítására valóalkalmazása is. Ó
HU0301887A 2001-01-31 2001-03-09 Multi-particulate form of medicament, comprising at least two differently coated forms of pellet HU229291B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10104504 2001-01-31
DE10104880A DE10104880A1 (de) 2001-01-31 2001-02-01 Multipartikuläre Arzneiform, enthaltend mindestens zwei unterschiedlich überzogene Pelletformen
PCT/EP2001/002679 WO2002060415A1 (de) 2001-01-31 2001-03-09 Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen

Publications (3)

Publication Number Publication Date
HUP0301887A2 true HUP0301887A2 (hu) 2003-09-29
HUP0301887A3 HUP0301887A3 (en) 2006-07-28
HU229291B1 HU229291B1 (en) 2013-10-28

Family

ID=26008387

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301887A HU229291B1 (en) 2001-01-31 2001-03-09 Multi-particulate form of medicament, comprising at least two differently coated forms of pellet

Country Status (14)

Country Link
US (2) US6897205B2 (hu)
EP (1) EP1248599B1 (hu)
JP (1) JP5502254B2 (hu)
KR (1) KR100507946B1 (hu)
AT (1) ATE380022T1 (hu)
CA (1) CA2403670C (hu)
DE (1) DE50113344D1 (hu)
ES (1) ES2298236T3 (hu)
HU (1) HU229291B1 (hu)
IL (1) IL151150A0 (hu)
MX (1) MXPA02009478A (hu)
PL (1) PL201766B1 (hu)
SK (1) SK287902B6 (hu)
WO (1) WO2002060415A1 (hu)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100389752C (zh) * 1978-04-21 2008-05-28 莱博法姆公司 控释组合物
US8071128B2 (en) * 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
DE10220470A1 (de) * 2002-04-30 2003-11-20 Roehm Gmbh ph-sensitives Polymer
DE19961334A1 (de) * 1999-12-17 2001-06-21 Roehm Gmbh Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere
DE10011447A1 (de) * 2000-03-10 2001-09-20 Roehm Gmbh Dispersion mit nichtionischem Emulgator
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
PL201766B1 (pl) * 2001-01-31 2009-05-29 Roehm Gmbh Wielocząsteczkowa postać leku zawierająca przynajmniej dwa typy granulek powlekanych w odmienny sposób oraz jej zastosowanie
DE10127134A1 (de) * 2001-06-05 2002-12-12 Roehm Gmbh verfahren zur Herstellung von Formkörpern aus (Meth)acrylat-Copolymeren mittels Spritzguß
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
DE10214002A1 (de) * 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP2596792A1 (en) * 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
BR0315657A (pt) * 2002-10-25 2005-09-13 Labopharm Inc Formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
JP4494712B2 (ja) * 2002-11-12 2010-06-30 大日本住友製薬株式会社 マルチプルユニット型徐放性製剤
DE10260920A1 (de) * 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zur Herstellung von Arnzeiformen oder Nahrungsergänzungsmitteln mit pigmentierten Polymerüberzügen
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
MXPA04010956A (es) * 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
MY162623A (en) * 2003-02-10 2017-06-30 Biogen Ma Inc Immunoglobulin formulation and method of preparation thereof
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
PT2210605T (pt) 2003-11-04 2017-04-24 Tcd Royalty Sub Llc Formas de dosagem única diária de tróspio
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
AT500144A1 (de) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
DE102004035936A1 (de) * 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (en) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DE102005000719A1 (de) * 2005-01-03 2006-07-20 Nextpharma Gmbh Pharmazeutische Zusammensetzung zur kontrollierten Freisetzung von ß-Lactam-Antibiotika in Kombination mit ß-Lactamase-Inhibitoren
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
CN101111230B (zh) * 2005-03-29 2010-05-19 赢创罗姆有限责任公司 包含对活性成分具有调节释放作用的小丸的多颗粒药用形式
KR20070119658A (ko) * 2005-03-29 2007-12-20 에보니크 룀 게엠베하 활성 성분 방출에 대한 조절 효과를 가지는 물질을포함하는 펠렛을 포함하는 다중 미립자 제약 형태
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
PT1883396E (pt) 2005-05-18 2013-10-08 Centre Nat Rech Scient Administração colónica de adsorventes
CA2611938A1 (en) * 2005-06-13 2007-01-25 Elan Corporation, Plc Modified release ticlopidine compositions
AU2006259224B2 (en) 2005-06-16 2012-08-23 Mohammed Saeed Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
CA2613107A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
US8298565B2 (en) 2005-07-15 2012-10-30 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US8865197B2 (en) * 2005-09-06 2014-10-21 Israel Oceanographic And Limnological Research Ltd. Food formulation for aquatic animals with integrated targeted delivery of bioactive agents
BRPI0615860B8 (pt) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
CA2638914C (en) 2006-02-09 2014-04-08 Alba Therapeutics Corporation Formulations for a tight junction effector
PL2019657T3 (pl) 2006-04-26 2015-10-30 Micell Technologies Inc Powłoki zawierające wiele leków
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20070292510A1 (en) * 2006-06-19 2007-12-20 Hugh Huang Enteric coated particles containing an active ingredient
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
UY30636A1 (es) * 2006-10-18 2008-05-02 Senosiain Lab Composision farmaceutica de liberacon modificada de un musculo relajante y un aine
CN101678388B (zh) 2006-10-23 2013-12-11 米歇尔技术公司 用于在涂覆过程中为基底充电的保持器
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
WO2008068778A2 (en) * 2006-12-05 2008-06-12 Alembic Limited Extended release pharmaceutical composition of pramipexole
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
BRPI0700133A (pt) * 2007-01-29 2008-09-16 Incrementha P D & I Pesquisa D composição farmacêutica compreendendo tramadol e cetoprofeno em combinação
SI2120878T1 (sl) * 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
JP5452236B2 (ja) * 2007-03-02 2014-03-26 ファーナム・カンパニーズ・インコーポレーテッド ロウ様物質を用いた徐放性組成物
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
ES2759626T3 (es) 2007-05-07 2020-05-11 Evonik Operations Gmbh Formas farmacéuticas sólidas que comprenden un recubrimiento entérico con liberación acelerada del fármaco
EP2170418B1 (en) * 2007-05-25 2016-03-16 Micell Technologies, Inc. Polymer films for medical device coating
US20110130822A1 (en) * 2007-07-20 2011-06-02 Orbusneich Medical, Inc. Bioabsorbable Polymeric Compositions and Medical Devices
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
EP2200611A4 (en) * 2007-09-14 2010-09-22 Biogen Idec Inc COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE MULTIFOCAL LEUCOENCEPHALEPATHY (PML)
KR20170097787A (ko) * 2007-10-12 2017-08-28 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
AR070863A1 (es) * 2008-03-11 2010-05-12 Takeda Pharmaceutical Preparacion solida de desintegracion oral y metodo para suprimir la ruptura de los granulos finos durante la produccion de un comprimido
MX2010011485A (es) 2008-04-17 2011-03-01 Micell Technologies Inc Stents que contienen capas bioadsorbibles.
AU2009270849B2 (en) 2008-07-17 2013-11-21 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US10668012B2 (en) * 2008-09-04 2020-06-02 Farnam Companies, Inc. Chewable sustained release formulations
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068256A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-substance
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
DE102008048729A1 (de) * 2008-09-24 2010-03-25 Add Technologies Ltd Advanced Drug Delivery Multipartikuläre Tabletten und Verfahren zur deren Herstellung
WO2010077908A1 (en) * 2008-12-17 2010-07-08 Altheus Therapeutics, Inc. Oral formulations
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
EP2411440B1 (en) * 2009-03-23 2018-01-17 Micell Technologies, Inc. Improved biodegradable polymers
WO2010111232A2 (en) 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
WO2010132707A1 (en) * 2009-05-14 2010-11-18 Orbusneich Medical, Inc. Self-expanding stent with polygon transition zone
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US8865213B2 (en) * 2009-12-30 2014-10-21 Usv Limited Modified release pharmaceutical compositions
TW201127375A (en) * 2010-01-08 2011-08-16 Eurand Inc Taste masked topiramate composition and an orally disintegrating tablet comprising the same
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
EP2371356B1 (en) 2010-03-12 2012-12-19 Phoeme GmbH Multi-particle pharmaceutical formulation for colon absorption
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
BR112012030641B8 (pt) * 2010-06-01 2022-06-14 Geistlich Pharma Ag Usos e composições para terapia farmacêutica oral
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
HU230560B1 (hu) * 2010-07-30 2016-12-28 Péter Hajnal pH-függő szakaszos és nyújtott hatóanyagleadású gyógyszerkészítmény
US20120164233A1 (en) 2010-07-30 2012-06-28 Ranbaxy Laboratories Limited Pulsatile release pharmaceutical formulation of dexlansoprazole
CA2823355C (en) 2010-12-30 2017-08-22 Micell Technologies, Inc. Nanoparticle and surface-modified particulate coatings, coated balloons, and methods therefore
EP2696815B1 (en) 2011-04-13 2019-03-20 Micell Technologies, Inc. Stents having controlled elution
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN110269959A (zh) 2013-03-12 2019-09-24 脉胜医疗技术公司 可生物吸收的生物医学植入物
JP6294457B2 (ja) * 2013-03-15 2018-03-14 ワーナー チルコット カンパニー， エルエルシーＷａｒｎｅｒ Ｃｈｉｌｃｏｔｔ Ｃｏｍｐａｎｙ， Ｌｌｃ 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物
CA2912387C (en) 2013-05-15 2019-04-16 Micell Technologies, Inc. Bioabsorbable biomedical implants
US20170143743A1 (en) * 2014-06-16 2017-05-25 Valpharma International S.P.A. Formulation for oral administration containing mesalazine
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
BR112017025148A2 (pt) 2015-06-05 2018-08-07 Evonik Röhm Gmbh composição farmacêutica ou nutracêutica com resistência contra a influência do etanol
CN105663091A (zh) * 2016-01-28 2016-06-15 上海信谊百路达药业有限公司 一种布地奈德肠溶缓释胶囊及其制备方法
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
CN110201242A (zh) 2016-02-08 2019-09-06 祥丰医疗私人有限公司 一种医疗装置
JP7021108B2 (ja) * 2016-04-19 2022-02-16 コナリス リサーチ インスティテュート アクチェンゲゼルシャフト ニコチンアミドの経口薬学的組成物
RU2744576C2 (ru) * 2016-04-19 2021-03-11 Ферринг Б.В. Пероральные фармацевтические композиции месалазина
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20180085498A1 (en) 2016-09-23 2018-03-29 Micell Technologies, Inc. Prolonged drug-eluting products
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3862032A1 (en) 2020-02-07 2021-08-11 Micell Technologies, Inc. Stents having biodegradable layers
CN111759552A (zh) 2020-07-06 2020-10-13 苏州莱诺医疗器械有限公司 一种可吸收支架系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58983D0 (da) * 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
JPS604120A (ja) * 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
IT1245889B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
JP2000507613A (ja) * 1996-11-01 2000-06-20 アイレックス・オンコロジー・インコーポレイテッド Ｄｆｍｏ含有持続放出配合物
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
SE9901387D0 (sv) * 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
PL201766B1 (pl) * 2001-01-31 2009-05-29 Roehm Gmbh Wielocząsteczkowa postać leku zawierająca przynajmniej dwa typy granulek powlekanych w odmienny sposób oraz jej zastosowanie

Also Published As

Publication number Publication date
HUP0301887A3 (en) 2006-07-28
KR20030009407A (ko) 2003-01-29
MXPA02009478A (es) 2003-03-10
IL151150A0 (en) 2003-04-10
SK13742002A3 (sk) 2004-05-04
US7438929B2 (en) 2008-10-21
CA2403670C (en) 2010-02-09
PL356962A1 (en) 2004-07-12
PL201766B1 (pl) 2009-05-29
US20030152627A1 (en) 2003-08-14
JP2004517156A (ja) 2004-06-10
US20050053660A1 (en) 2005-03-10
CA2403670A1 (en) 2002-08-08
ATE380022T1 (de) 2007-12-15
DE50113344D1 (de) 2008-01-17
WO2002060415A1 (de) 2002-08-08
ES2298236T3 (es) 2008-05-16
EP1248599A1 (de) 2002-10-16
HU229291B1 (en) 2013-10-28
KR100507946B1 (ko) 2005-08-17
SK287902B6 (sk) 2012-03-02
US6897205B2 (en) 2005-05-24
EP1248599B1 (de) 2007-12-05
JP5502254B2 (ja) 2014-05-28

Similar Documents

Publication Publication Date Title
HUP0301887A2 (hu) Több részecskébżl álló gyógyszerforma, amely legalább két különbözżen bevont pelletformát tartalmaz
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
HUP0002744A2 (hu) Gyors hatóanyag-leadású és ízmaszkírozó gyógyászati dózisforma
HUP0301192A2 (hu) Topiramátot tartalmazó gyógyászati készítmény és eljárás az előállítására
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
HK1111609A1 (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
HUP9802828A2 (hu) Belélegezhető vivőanyag szabályozott hatóanyag-leadású gyógyszerkészítményekhez
EP2263660A3 (en) Orally disintegrable tablets
HUP0402230A2 (hu) Többszörös bevonattal ellátott gyógyszer dózisforma
MXPA02010332A (es) Composicion de recubrimiento para enmascarar el sabor.
BR0112532A (pt) Composição farmacêutica oral, sistema galênico e uso da composição
EP0282011A2 (en) Sustained release pharmaceutical dosage forms
HUP0201765A2 (hu) Maszkírozott ízű folyékony gyógyszerkészítmények
CY1107576T1 (el) Ταχεια αποδεσμευση των υδατοδιαλυτων φαρμακευτικων ουσιων
HUP0401569A2 (hu) Amlodipint és atorvastatint tartalmazó gyógyászati készítmények és eljárás az előállításukra
JP2005503399A5 (hu)
JP2005528430A5 (hu)
RU2004105263A (ru) Фармацевтические композиции, содержащие тербинафин, и их применение
HK1060691A1 (en) Ion-strength independent sustained release pharmaceutical formulation
CA2459165A1 (en) Dosage forms having prolonged active ingredient release
ES2261006A1 (es) Pellet multicapa de liberacion controlada de metilfenidato.
WO2002062299A3 (en) Improved controlled release oral dosage form
HUP0300970A2 (hu) Epinastint és pszeudoefedrint tartalmazó új gyógyszerkészítmények
JP2002516616A (ja) 活性成分として単数または複数の抗感染症薬と微生物とを含む安定な固定薬用量の医薬組成物の製造法
BR0109640A (pt) Forma de droga multiparticulada compreendendo pelo menos duas formas de pélete diferentemente revestidas

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: EVONIK ROEHM GMBH, DE

Free format text: FORMER OWNER(S): ROEHM GMBH & CO. KG, DE